Comparative efficacy of secukinumab against adalimumab and infliximab in patients with moderate-to-severe plaque psoriasis

Pan, Ran; Wang, Xiaolun; Shu, Min; Das, Jaydeep; Kalra, Manik; Wang, Zhidong

doi:10.1097/cm9.0000000000001817

Cited by 5 publications

(5 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We identified 28 MAs/NMAs published between January 2021 and May 2023, investigating and comparing the effect of systemic therapies for moderate-to-severe adult plaque psoriasis [ 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 ]. A total of 10 analyses were excluded for the following reasons: insufficient information on the compared therapies in the abstract, the absence of the full text [ 28 , 29 , 30 ], the full text being in a language other than English [ 31 ], being a comparison to a placebo [ 32 , 33 , 34 , 35 , 36 ], or the absence of a direct comparison between therapies [ 37 ].…”

Section: Resultsmentioning

confidence: 99%

Comparing Meta-Analyses with ChatGPT in the Evaluation of the Effectiveness and Tolerance of Systemic Therapies in Moderate-to-Severe Plaque Psoriasis

Lam Hoai,

Simonart

2023

JCM

View full text Add to dashboard Cite

Background: Meta-analyses (MAs) and network meta-analyses (NMAs) are high-quality studies for assessing drug efficacy, but they are time-consuming and may be affected by biases. The capacity of artificial intelligence to aggregate huge amounts of information is emerging as particularly interesting for processing the volume of information needed to generate MAs. In this study, we analyzed whether the chatbot ChatGPT is able to summarize information in a useful fashion for providers and patients in a way that matches up with the results of MAs/NMAs. Methods: We included 16 studies (13 NMAs and 3 MAs) that evaluate biologics (n = 6) and both biologic and systemic treatment (n = 10) for moderate-to-severe psoriasis, published between January 2021 and May 2023. Results: The conclusions of the MAs/NMAs were compared to ChatGPT’s answers to queries about the molecules evaluated in the selected MAs/NMAs. The reproducibility between the results of ChatGPT and the MAs/NMAs was random regarding drug safety. Regarding efficacy, ChatGPT reached the same conclusion as 5 out of the 16 studies (four out of four studies when three molecules were compared), gave acceptable answers in 7 out of 16 studies, and was inconclusive in 4 out of 16 studies. Conclusions: ChatGPT can generate conclusions that are similar to MAs when the efficacy of fewer drugs is compared but is still unable to summarize information in a way that matches up to the results of MAs/NMAs when more than three molecules are compared.

show abstract

Section: Resultsmentioning

confidence: 99%

Comparing Meta-Analyses with ChatGPT in the Evaluation of the Effectiveness and Tolerance of Systemic Therapies in Moderate-to-Severe Plaque Psoriasis

Lam Hoai,

Simonart

2023

JCM

View full text Add to dashboard Cite

show abstract

“…For guselkumab, none of the identified studies reported data for the Chinese subpopulation at the time of analysis. Therefore, previously published network meta-analysis (NMA) by Pan et al [ 36 ] was updated with a wider scope in January 2022 to identify the latest evidence on comparative efficacy of secukinumab and all other biologics for the treatment of moderate-to-severe plaque psoriasis (Table 2 ). Bayesian NMA method was used to combine evidence from the identified randomized controlled trials (RCTs).…”

Section: Methodsmentioning

confidence: 99%

“…For each intervention, the proportion of patients achieving PASI response rate is reported b Efficacy data for all interventions except guselkumab was obtained from a published mixed-treatment comparison conducted with RCTs involving Chinese patients with moderate-to-severe plaque psoriasis [ 35 ]. For guselkumab, efficacy inputs were obtained by updating the NMA published by Pan et al [ 36 ] in January 2022. Study details are reported in Supplementary Appendix A c PASI response rate for the secukinumab arm was assumed to be a weighted average of the response rate for patients receiving secukinumab 150 mg and those receiving 300 mg in the ratio of 32.3% and 67.7%, respectively.…”

Section: Methodsmentioning

confidence: 99%

“…b Efficacy data for all interventions except guselkumab was obtained from a published mixed-treatment comparison conducted with RCTs involving Chinese patients with moderate-to-severe plaque psoriasis [ 35 ]. For guselkumab, efficacy inputs were obtained by updating the NMA published by Pan et al [ 36 ] in January 2022. Study details are reported in Supplementary Appendix A…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Moderate-to-Severe Plaque Psoriasis: The Chinese Healthcare System Perspective

Zhang,

Xia,

Guo

et al. 2023

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Introduction This study assessed the cost-effectiveness of secukinumab compared with other biologics (adalimumab, infliximab, ustekinumab, ixekizumab, guselkumab, and Yisaipu [etanercept biosimilar]) for moderate-to-severe plaque psoriasis from the Chinese healthcare system perspective. Methods A decision-tree (first year)/Markov model (subsequent years), with an annual cycle, was implemented over a lifetime horizon. The Psoriasis Area and Severity Index (PASI) response rate at week 16 was used for treatment response. Efficacy inputs were obtained from a mixed-treatment comparison conducted using data from randomized controlled trials. Other clinical inputs (adverse events, dropout, and mortality rates), utility weights, and costs were derived from published literature and local Chinese sources. Both costs and outcomes were discounted at 5% per annum. Model outcomes included quality-adjusted life years (QALYs) and incremental cost-effectiveness ratio (ICER). One-way and probabilistic sensitivity analyses were conducted to test the robustness of results. Results For patients with moderate-to-severe psoriasis, secukinumab generated the highest QALYs (12.334) against all comparators at a lifetime cost of ¥231,477. Secukinumab dominated (higher QALYs at lower costs) all other biologics except ixekizumab in this population. Compared with secukinumab, ixekizumab incurred slightly lower costs (¥228,320) but gained lesser QALYs (12.284). Thus, secukinumab was a cost-effective treatment than ixekizumab at a willingness-to-pay (WTP) threshold of ¥257,094 per QALY gained. In the one-way sensitivity analysis, base-case results were most sensitive to changes in the PASI response at 16 weeks and year 2+ dropout rates. Conclusion Secukinumab is the most cost-effective treatment option for patients with moderate-to-severe psoriasis compared with other commonly used biologics from the Chinese healthcare system perspective. Supplementary Information The online version contains supplementary material available at 10.1007/s13555-023-01041-8.

show abstract

“…137,164 Infliximab, another TNF inhibitor, has also been shown to be effective in the treatment of paediatric psoriasis. [193][194][195][196] Infliximab is administered via intravenous infusion. 194 The recommended dose is 5 mg/kg at weeks 0, 2, and 6 and every 8 weeks thereafter.…”

Section: Fumaric Acid Estersmentioning

confidence: 99%

Childhood guttate psoriasis: an updated review

Leung,

Barankin,

Lam

et al. 2023

DIC

View full text Add to dashboard Cite

Background Guttate psoriasis is common and affects 0.5–2% of individuals in the paediatric age group. This review aims to familiarize physicians with the clinical manifestations, evaluation, diagnosis and proper management of guttate psoriasis. Methods A search was conducted in July 2023 in PubMed Clinical Queries using the key term “guttate psoriasis”. The search strategy included all observational studies, clinical trials and reviews published within the past 10 years. The information retrieved from the search was used in the compilation of the present article. Results Guttate psoriasis typically presents with an abrupt onset of numerous, small, scattered, tear-drop-shaped, scaly, erythematous, pruritic papules and plaques. Sites of predilection include the trunk and proximal extremities. There may be a history of preceding streptococcal infection. Koebner phenomenon is characteristic. Guttate psoriasis may spontaneously remit within 3–4 months with no residual scarring, may intermittently recur and, in 40–50% of cases, may persist and progress to chronic plaque psoriasis. Given the possibility for spontaneous remission within several months, active treatment may not be necessary except for cosmetic purposes or because of pruritus. On the other hand, given the high rates of persistence of guttate psoriasis and progression to chronic plaque psoriasis, some authors suggest active treatment of this condition. Conclusion Various treatment options are available for guttate psoriasis. Triggering and exacerbating factors should be avoided if possible. Topical corticosteroids alone or in combination with other topical agents (e.g. tazarotene and vitamin D analogues) are the most rapid and efficient treatment for guttate psoriasis and are therefore the first-line treatment for mild cases. Other topical therapies include vitamin D analogues, calcineurin inhibitors, anthralin, coal tar and tazarotene. Ultraviolet phototherapy is the first-line therapy for moderate-to-severe guttate psoriasis, as it is more practical than topical therapy when treating widespread or numerous small lesions. Systemic immunosuppressive and immunomodulatory therapies (e.g. methotrexate, cyclosporine, retinoids, fumaric acid esters and biologics) may be considered for patients with moderate-to-severe guttate psoriasis who fail to respond to phototherapy and topical therapies.

show abstract

Comparative efficacy of secukinumab against adalimumab and infliximab in patients with moderate-to-severe plaque psoriasis

Abstract: Supplemental Digital Content is available in the text

Cited by 5 publications

References 30 publications

Comparing Meta-Analyses with ChatGPT in the Evaluation of the Effectiveness and Tolerance of Systemic Therapies in Moderate-to-Severe Plaque Psoriasis

Comparing Meta-Analyses with ChatGPT in the Evaluation of the Effectiveness and Tolerance of Systemic Therapies in Moderate-to-Severe Plaque Psoriasis

Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Moderate-to-Severe Plaque Psoriasis: The Chinese Healthcare System Perspective

Childhood guttate psoriasis: an updated review

Contact Info

Product

Resources

About